A Study for Safety and Efficacy of Miltefosine for Treatment of Children and Adolescents With Post-Kala-azar Dermal Leishmaniasis (PKDL) in Bangladesh and Association of Serum Vitamin E and Exposure to Arsenic With PKDL
Phase of Trial: Phase III
Latest Information Update: 31 Aug 2017
At a glance
- Drugs Miltefosine (Primary)
- Indications Leishmaniasis; Visceral leishmaniasis
- Focus Adverse reactions; Therapeutic Use
- 28 Aug 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.
- 28 Aug 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
- 10 Jun 2017 Biomarkers information updated